Lytenava: How FDA Approval Could Reshape the Ophthalmic Anti-VEGF Market

Key Takeaways

• FDA-approved bevacizumab: Lytenava gives retina specialists an FDA-approved ophthalmic formulation of bevacizumab for wet AMD, a drug already widely used off-label in retinal care.
• Compounded Avastin remains relevant: Cost, existing practice processes, and Lytenava's current wet AMD application mean compounded bevacizumab is unlikely to disappear overnight.
• Regulation could influence adoption: The arrival of an FDA-approved ophthalmic formulation creates new considerations around the use and compounding of bevacizumab under 503A and 503B rules.
• Lytenava enters a highly competitive field: Aflibercept and faricimab continue to compete on treatment durability, while Lytenava's opportunity is focused more on access and standardization.
• Specialist talent will support adoption: Market access, HEOR, medical affairs, regulatory affairs, and commercial expertise will all play a role as the product moves towards launch.

For more than two decades, bevacizumab has played an important role in retinal care despite being developed and approved for oncology rather than ophthalmology. Its off-label use, particularly in wet age-related macular degeneration (AMD), has been supported by its accessibility and relatively low cost.

That long-established model changed in July 2026 when the FDA approved Lytenava (bevacizumab-vikg), the first FDA-approved ophthalmic formulation of bevacizumab for wet AMD in the US. The approval gives retina specialists an ophthalmic-specific option, with its safety, effectiveness, and manufacturing quality assessed through the FDA approval process.

The question now is whether bevacizumab will gradually move from a compounded, off-label supply model towards an FDA-approved commercial product and what that could mean for the wider anti-VEGF market.

Why Does Lytenava Matter for Retinal Care?

Bevacizumab Was Already Widely Used in Retina Care

Unlike many new ophthalmic therapies, Lytenava is not introducing retina specialists to an unfamiliar molecule or mechanism. Bevacizumab is already widely used as an anti-VEGF treatment in retinal care, particularly where cost is an important consideration. The difference is that Avastin was developed as an intravenous oncology product, while Lytenava has been developed specifically for intravitreal administration.

This matters because the use of off-label Avastin has created an established way of working across retinal practices. Bevacizumab is typically repackaged by a compounding pharmacy into doses suitable for intravitreal injection. Practices have built procurement processes, supplier relationships, and financial arrangements around that model. Lytenava needs to give practices a reason to change a system that is already familiar and well established.

What Does FDA Approval Change?

FDA approval gives Lytenava a level of regulatory oversight that compounded bevacizumab does not have. Compounded drugs are not FDA-approved, meaning the FDA does not review them for safety, effectiveness, or quality before they are marketed. The FDA has highlighted risks associated with poor compounding practices, including contamination and incorrect amounts of active ingredient.

Lytenava therefore gives retina practices a clear distinction between a purpose-built ophthalmic product and a compounded version of a drug originally developed for intravenous oncology use.

However, FDA approval is not the only factor that will determine whether practices switch. Pricing, reimbursement, availability, and physician confidence will all influence adoption. Outlook Therapeutics is targeting a US launch before the end of 2026 and submitted an application for a permanent product-specific J-code in October, making reimbursement an important part of the next stage of the product's development.

Can Lytenava Replace Off-Label Avastin?

Why Cost Will Keep Compounded Bevacizumab Relevant

Compounded bevacizumab has traditionally offered a much lower-cost way of delivering anti-VEGF treatment than many branded alternatives, but Lytenava enters the market with a different cost structure. An FDA-approved commercial product must cover the costs of clinical development, manufacturing, regulatory oversight, distribution, and commercial support. That means Lytenava must demonstrate enough value for practices to justify moving away from a lower-cost model.

This makes reimbursement particularly important, as a retina practice deciding whether to adopt Lytenava will need to consider payer coverage, coding, patient out-of-pocket costs, and the practical work involved in introducing a new product.

If Lytenava becomes part of step-therapy protocols or receives strong reimbursement, practices may have a stronger incentive to use it. If payers continue to favor lower-cost compounded bevacizumab, the transition could be slower.

What Do 503A and 503B Rules Mean for Compounded Bevacizumab?

The arrival of Lytenava also changes the regulatory considerations surrounding compounded bevacizumab. The distinction between Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act is crucial:

• Section 503A generally covers traditional pharmacy compounding for individual patients based on prescriptions.
• Section 503B covers outsourcing facilities that can compound drugs without receiving prescriptions for individual patients.

One important issue is whether a compounded drug is considered “essentially a copy” of an FDA-approved product. Under the 503B framework, an outsourcing facility cannot generally compound a drug that is “essentially a copy” of an approved product if it wants to qualify for the relevant exemptions. Section 503A also places restrictions around drugs that are “essentially copies” of products available commercially.

Compounded bevacizumab hasn’t become unlawful overnight, but the existence of an FDA-approved ophthalmic formulation changes the compliance considerations for compounders. There are also circumstances where a compounded product may be permitted because it is clinically different for an individual patient, alongside other conditions and exemptions.

Why Wet AMD Is Only the Starting Point

Lytenava is currently approved only for wet AMD. Even though this is one of the most common reasons eye specialists use bevacizumab, clinicians still use the drug off-label for several other eye conditions not covered by this official approval, such as diabetic macular edema (DME) and retinal vein occlusion (RVO). That means Lytenava cannot simply replace every dose of compounded bevacizumab currently used by retina practices.

Lytenava may become the preferred bevacizumab option for wet AMD within its approved indication, while compounded bevacizumab or other anti-VEGF therapies continue to have roles in other clinical circumstances.

Where Does Lytenava Fit in the Anti-VEGF Market?

Lytenava's main opportunity is not to compete directly with every newer anti-VEGF therapy. The ophthalmic market increasingly includes treatments designed to extend treatment intervals, with aflibercept and faricimab among the therapies competing on durability.

Lytenava enters from a different position. It provides an FDA-approved ophthalmic version of a molecule retina specialists already know and have been using as a lower-cost anti-VEGF treatment. It doesn’t need to match the dosing intervals of higher-durability therapies to compete if it can establish itself as a trusted option for patients who would otherwise receive compounded bevacizumab.

In that sense, Lytenava could become a new benchmark for where bevacizumab sits within retinal treatment rather than a direct challenger to every therapy in the anti-VEGF market.

What Does Lytenava Mean for Ophthalmology Talent?

The next challenges for Lytenava are commercial supply, reimbursement, distribution, and adoption. Success will require professionals who understand both the clinical side of the product and the practical requirements of bringing it to market. Market Access and Health Economics and Outcomes Research (HEOR) professionals can help build the reimbursement case, while regulatory, medical affairs, and commercial teams support launch and adoption.

CSG Talent’s dedicated Ophthalmology specialists help organizations secure specialist talent across technical, commercial, and leadership roles, combining sector knowledge with a detailed understanding of the talent market.

Contact CSG Talent to discuss your Ophthalmology and MedTech talent requirements.

Frequently Asked Questions About Lytenava

What is Lytenava?

Lytenava (bevacizumab-vikg) is the first FDA-approved ophthalmic formulation of bevacizumab in the US, approved for neovascular (wet) AMD.

Is Lytenava the same as Avastin?

Both contain bevacizumab, but Avastin was developed for intravenous oncology use and is used off-label in ophthalmology. Lytenava was developed specifically for ophthalmic use.

Will Lytenava replace compounded Avastin?

Not entirely. Cost, reimbursement, and physician adoption will impact usage, while compounded bevacizumab may continue to be used for other off-label retinal purposes.

What is the difference between 503A and 503B compounding?

503A generally covers traditional pharmacy compounding for individual patients, while 503B applies to outsourcing facilities subject to additional FDA requirements and restrictions.

What could Lytenava mean for the ophthalmology market?

Lytenava could shift some bevacizumab use from a compounded, off-label model towards an FDA-approved commercial product, creating new opportunities across ophthalmology and MedTech.